Inferior ways used to evaluate clinical-stage biotech firms are those that ignore the sciences, the technologies and the promising results from the products in clinical trials. It reached a stage where assessors are even ignoring the value of the approval of biotech firms’ products that succeeded in treating diseases that are yet to find treatments.

We have Superior News from Blueprint Medicines
The U.S. Food and Drug Administration (FDA) has approved Blueprint Medicines' (This content is for paid subscribers.